Evidence map›Paper›PMID 23555976›Full record

ArticlePloS one2013

Mesenchymal stem cells engineered to inhibit complement-mediated damage.

Melisa A Soland, Mariana Bego, Evan Colletti, Esmail D Zanjani, Stephen St Jeor, Christopher D Porada, Graça Almeida-Porada

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Tafazzin deficiency in mouse mesenchymal stem cells promote reprogramming of activated B lymphocytes toward immunosuppressive phenotypes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Melisa A SolandWake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America.
Mariana Bego
Evan Colletti
Esmail D Zanjani
Stephen St Jeor
Christopher D Porada
Graça Almeida-Porada
University of Nevada, Reno · USWake Forest University · USForest Institute · USMontreal Clinical Research Institute · CA

Funding

In Utero Stem Cell Transplantation for Hemophilia AR01HL073737 · NHLBI · UNIVERSITY OF NEVADA RENO · PI ALMEIDA-PORADA, GRACA DUARTE · 2003 to 2006
$1.8M
Functional Analysis of the Hematopoietic Niche during OntogenyR01HL097623 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ALMEIDA-PORADA, GRACA DUARTE · 2009 to 2012
$1.4M
NHLBI NIH HHS HL73737NHLBI NIH HHS HL97623NHLBI NIH HHS R01 HL073737NHLBI NIH HHS R01 HL097623
6 · The paper itself

Abstract

Mesenchymal stem cells (MSC) preferentially migrate to damaged tissues and, due to their immunomodulatory and trophic properties, contribute to tissue repair. Although MSC express molecules, such as membrane cofactor protein (CD46), complement decay-accelerating factor (CD55), and protectin (CD59), which confer protection from complement-mediated lysis, MSC are recruited and activated by anaphylatoxins after transplantation, potentially causing MSC death and limiting therapeutic benefit. We have previously demonstrated that transduction of MSC with a retrovirus encoding HCMV-US proteins resulted in higher levels of MSC engraftment due to decreased HLA-I expression. Here, we investigate whether engineering MSC to express US2 (MSC-US2), US3 (MSC-US3), US6 (MSC-US6), or US11 (MSC-US11) HCMV proteins can alter complement recognition, thereby better protecting MSC from complement attack and lysis. HCMV-US proteins increased MSC CD59 expression at different levels as determined by flow cytometric evaluation of the median fluorescence intensity ratio (MFI). A significant increase in CD59 expression was seen in MSC-US2, MSC-US3, and MSC-US6, but not in MSC-US11. Only MSC-US2 displayed increased expression of CD46, while US2 and US3 proteins were both able to augment the percentage of MSC expressing this molecule. Regardless of the HCMV protein expressed, none changed CD55 MFI; however, expression of US6, US11, and US2 each increased the percentage of MSC that were positive for this molecule. Because US2 protein was the most efficient in up-regulating all three complement regulatory proteins, we used a functional complement-mediated cytotoxicity assay to investigate whether MSC-US2 were protected from complement-mediated lysis. We demonstrated that over-expression of the US2 protein reduced complement lysis by 59.10±12.89% when compared to untransduced MSC. This is the first report, to our knowledge, describing a role of HCMV-US proteins in complement evasion, and our data shows that over-expression of US2 protein on MSC could serve as a strategy to protect these cells from complement lysis.

Indexed as

CD55 AntigensCD59 AntigensCell EngineeringCells, CulturedComplement System ProteinsCytomegalovirusGenetic VectorsGlycoproteinsHumansImmediate-Early ProteinsMembrane Cofactor ProteinMembrane ProteinsMesenchymal Stem CellsRNA-Binding ProteinsTransduction, GeneticViral Envelope ProteinsCD55 AntigensCD59 AntigensComplement System ProteinsGlycoproteinsImmediate-Early ProteinsMembrane Cofactor ProteinMembrane ProteinsRNA-Binding ProteinsUS11 protein, herpesvirusUS2 protein, VaricellovirusUS3 protein, cytomegalovirusUS6 protein, Human cytomegalovirusViral Envelope ProteinsViral Proteins

Identifiers

PMID23555976
PMCPMC3608620
OpenAlexW2032496521

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.